Novartis’ Cosentyx (secukinumab) is one step closer to becoming a new treatment option for adolescents living with moderate to severe hidradenitis suppurativa (HS) in Europe, following a positive recommendation from a key European medicines regulatory committee.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorisation of Cosentyx for adolescents aged 12 years and older with active moderate to severe HS who have not responded adequately to conventional systemic therapy.
If approved by the European Commission (EC), Cosentyx would become the only interleukin-17A (IL-17A) inhibitor approved for adolescent HS in Europe and the first innovative biologic treatment option for this age group in nearly a decade. The recommendation marks a significant potential advance for young patients who have faced limited treatment choices.
Hidradenitis suppurativa is a chronic, systemic and progressive inflammatory skin disease that can cause severe pain, recurring boil-like abscesses and open wounds. These lesions can develop in intimate areas of the body and leave permanent, irreversible scars. The disease frequently begins early in life, with more than 50% of cases emerging during puberty.
"Hidradenitis suppurativa often begins during adolescence, a critical period when the disease can progress to irreversible scarring, yet we currently have limited treatment options for this age group,” said John Ingram, Clinical Professor, Cardiff University School of Medicine, United Kingdom. “This positive CHMP opinion for secukinumab represents an important step toward addressing a meaningful gap in care for young people living with this challenging disease."
The positive CHMP opinion is supported by evidence showing that weight-based dosing of Cosentyx in adolescents aged 12 years and older delivers drug exposure generally comparable to that seen in adults with HS.
The evidence package includes efficacy and safety findings from adult HS clinical studies, pharmacokinetic modelling based on adult HS and psoriasis trials, paediatric clinical trial data from other approved Cosentyx indications, and weight-based dosing analyses. The medicine also has an established safety profile across several approved adult and paediatric indications.
Novartis said the recommendation brings the company closer to expanding access to advanced treatment for young people affected by the disease.
"For over a decade, Cosentyx has helped transform outcomes across several immune-mediated diseases, including hidradenitis suppurativa. Adolescents living with moderate to severe HS deserve access to more advanced treatment options,” said Patrick Horber, President, International, Novartis.
“This positive CHMP opinion brings us closer to that goal in Europe, and we look forward to the European Commission decision in the coming months."
The European Commission is expected to deliver its final decision within approximately two months of the CHMP recommendation.